Cidofovir

Cidofovir
Clinical data
Trade names	Vistide
AHFS/Drugs.com	Monograph
Pregnancy; category	AU: D;
Routes of; administration	Intravenous
ATC code	J05AB12 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	complete
Protein binding	<6%
Elimination half-life	2.6 hours (active metabolites: 15–65 hours)
Excretion	renal The above pharmacokinetic parameters are measured for cidofovir used in conjunction with probenecid.
Identifiers
	IUPAC name ({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid;
CAS Number	113852-37-2 ;
PubChem CID	60613;
DrugBank	DB00369 ;
ChemSpider	54636 ;
UNII	768M1V522C;
KEGG	C06909 ;
ChEBI	CHEBI:3696 ;
ChEMBL	ChEMBL152 ;
NIAID ChemDB	001049;
CompTox Dashboard (EPA)	DTXSID3043734 ;
ECHA InfoCard	100.166.433
Chemical and physical data
Formula	C8H14N3O6P
Molar mass	279.189 g·mol−1
3D model (JSmol)	Interactive image;
Specific rotation	-97.3
Melting point	260 °C (500 °F)
	SMILES O=C1/N=C(\C=C/N1C[C@H](OCP(=O)(O)O)CO)N;
	InChI InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1 ; Key:VWFCHDSQECPREK-LURJTMIESA-N ;
	(verify)

Cidofovir, brand name Vistide, is a topical or injectable antiviral medication primarily used as a treatment for cytomegalovirus (CMV) retinitis (an infection of the retina of the eye) in people with AIDS.

Cidofovir was approved for medical use in 1996.